Preventive effect of taurine drug on liver transplant recipients

Phase 3

Recruiting

• Conditions: liver transplantation.; Other complications of liver transplant; T86.49

• Registration Number: IRCT20120731010453N3
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 3 April 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

All patients which candidate to liver transplant older than 18 years old

Exclusion Criteria

Re-transplantation or simultaneous liver and kidney transplantation
Hypersensitivity to taurine

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Occurrence of reperfusion syndrome during the surgery. Timepoint: During the surgery. Method of measurement: By reviewing patient information.;The required dose of norepinephrine during surgery in order to correct the hypotension. Timepoint: During the surgery. Method of measurement: By reviewing patient information.

Secondary Outcome Measures

Name	Time	Method
The functional state of the organ from the time of transplantation to the time of discharge. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.;Duration of hospitalization in the ICU hospital for CRRT or dialysis. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.;Mortality rate. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.;Need for CRRT or dialysis during hospitalization. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.